1.52
price down icon0.65%   -0.01
after-market After Hours: 1.56 0.04 +2.63%
loading
Nkarta Inc stock is traded at $1.52, with a volume of 1.02M. It is down -0.65% in the last 24 hours and down -33.62% over the past month. Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$1.53
Open:
$1.55
24h Volume:
1.02M
Relative Volume:
0.82
Market Cap:
$107.26M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.6333
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-16.48%
1M Performance:
-33.62%
6M Performance:
-71.75%
1Y Performance:
-87.56%
1-Day Range:
Value
$1.50
$1.56
1-Week Range:
Value
$1.50
$1.875
52-Week Range:
Value
$1.50
$13.90

Nkarta Inc Stock (NKTX) Company Profile

Name
Name
Nkarta Inc
Name
Phone
(925) 407-1049
Name
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Employee
159
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NKTX's Discussions on Twitter

Compare NKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTX
Nkarta Inc
1.52 107.26M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-24 Initiated Rodman & Renshaw Buy
Aug-14-24 Upgrade Raymond James Outperform → Strong Buy
Mar-22-24 Downgrade Raymond James Strong Buy → Outperform
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity Buy
Jul-28-22 Initiated Needham Buy
Jul-18-22 Initiated SVB Leerink Outperform
Mar-11-22 Initiated Raymond James Outperform
Mar-08-22 Initiated H.C. Wainwright Buy
Jan-06-22 Initiated William Blair Outperform
Nov-18-21 Initiated SMBC Nikko Outperform
Jul-16-21 Initiated Oppenheimer Outperform
Aug-04-20 Initiated Cowen Outperform
Aug-04-20 Initiated Evercore ISI Outperform
Aug-04-20 Initiated Mizuho Buy
Aug-04-20 Initiated Stifel Buy
View All

Nkarta Inc Stock (NKTX) Latest News

pulisher
09:35 AM

Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

09:35 AM
pulisher
Mar 17, 2025

Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

Nkarta (NKTX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 01, 2025

Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World

Mar 01, 2025
pulisher
Feb 25, 2025

Nkarta to Participate in March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 18, 2025

Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World

Feb 17, 2025
pulisher
Feb 16, 2025

Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World

Feb 16, 2025
pulisher
Feb 15, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Feb 15, 2025
pulisher
Feb 11, 2025

Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 11, 2025
pulisher
Feb 06, 2025

A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail

Feb 06, 2025
pulisher
Feb 05, 2025

Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex

Feb 04, 2025
pulisher
Jan 28, 2025

TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus.com

Jan 28, 2025
pulisher
Jan 27, 2025

What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register

Jan 27, 2025
pulisher
Jan 21, 2025

Nkarta's chief medical officer sells $19,003 in stock - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

Nkarta CEO Paul Hastings sells $38,231 in stock - MSN

Jan 21, 2025
pulisher
Jan 19, 2025

Nkarta executive sells shares worth $12,843 - MSN

Jan 19, 2025
pulisher
Jan 18, 2025

Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa

Jan 18, 2025
pulisher
Jan 17, 2025

Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta's chief technical officer sells $16,383 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World

Jan 17, 2025
pulisher
Jan 15, 2025

Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World

Jan 15, 2025

Nkarta Inc Stock (NKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):